ERBB2 and breast carcinoma: Although the survival data of TCGA-BRCA is considered immature in some studies [35], the AdhesionScore was also significantly higher in HER2-enriched breast carcinomas (p < 0.05, Kruskal–Wallis, Figure 5A) and effectively stratified patients by overall survival, with a 5-year survival rate of 93.39% in the low-risk group (CI: 90.1–96.8%) and an estimated risk of death of 6.61% (log-rank test, p = 0.011, Figure 5B).